

# Revisiting the Relationship between Short-Chain Fatty Acids, the Microbiota, and Colorectal Tumors

Running title: SCFAs and colorectal tumors

Marc A Sze<sup>1</sup>, Nicholas A Lesniak<sup>1</sup>, Mack T Ruffin IV<sup>2</sup>, Patrick D. Schloss<sup>1†</sup>

† To whom correspondence should be addressed: [pschloss@umich.edu](mailto:pschloss@umich.edu)

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109

<sup>2</sup> Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

## Abstract

**Background.** Colorectal cancer (CRC) is a growing health concern with the majority of the risk for developing disease being due to environmental factors. The microbiota is one of these environmental factors with certain bacterial community members being associated with CRC, while other taxa are associated to colons without tumors. Some of the taxa associated to colons without tumors can use fiber to produce short-chain fatty acids (SCFAs) that can inhibit tumor growth in model systems. However, the data supporting the importance of SCFAs in human CRC is less certain. Here, we test the hypothesis that SCFA concentrations are different in individuals with colorectal tumors.

**Methods.** We analyzed a cross-sectional (n=490) and longitudinal pre- and post-treatment (n=67) group for their concentrations of acetate, butyrate, and propionate. Analysis also included tumor classification models using Random Forest, imputed gene relative abundance with PICRUSt, and metagenomic sequencing on a subset (n=85) of the total cross-sectional group.

**Results.** No difference in SCFA concentrations were found between individuals without tumors and patients with adenomas or carcinomas (P-value > 0.15). There was no difference in classification models with or without SCFAs in their ability to predict patients with adenomas or carcinomas versus individuals without tumors (P-value > 0.05). Using metagenomic sequencing, there was also no difference in genes involved with SCFA synthesis between individuals without tumors and patients with adenomas or carcinomas (P-value > 0.70).

**Conclusions.** Although our data does not support the hypothesis that SCFAs are different in individuals that have colorectal tumors, there may be context specific scenarios where SCFAs may still be beneficial for treatment of CRC. Alternatively, there may be other mechanisms that have not been thoroughly investigated that are more important to the development of human CRC.

## 24 Introduction

25 Colorectal cancer (CRC) is currently the third highest cancer-related cause of death within the  
26 US (1, 2). Although there is a genetic component to the disease, the environment is attributed to  
27 being a larger risk factor for CRC (3). These environmental risk factors include but are not limited  
28 to smoking cigarettes, diet, and the microbiota (4–6). Many of these environmental risk factors  
29 are capable of being modified, and this has lead to the investigation of how the microbiota may  
30 exacerbate or cause tumorigensis (7–9) and whether the bacterial community is altered (10, 11).  
31 Multiple reports in case/control studies have identified bacterial taxa commonly associated with  
32 individuals without tumors to be decreased in patients with carcinoma tumors (11–13). Many of  
33 these taxa within individuals wihtout tumors actively produce short-chain fatty acids (SCFAs) from  
34 fiber that are a part of our general diet (14). The most extensively studied of these SCFAs are  
35 acetate, butyrate, and propionate (15). Overall, the specific bacterial taxa of the microbiota that  
36 create SCFAs are an attractive target to modulate the risk of CRC.

37 Specific SCFAs, like butyrate, have shown positive results for CRC treatment within model systems  
38 (16). Butyrate has been shown to inhibit cancer cell growth in *in vitro* systems (17). Additionally,  
39 supplementation with food sources that bacteria use to create these SCFAs may also be able to  
40 confer beneficial effects. For example, fiber supplementation in mouse models of CRC caused an  
41 overall reduction in tumor burden while also increasing SCFA concentrations (18). Although these  
42 model systems provide important preliminary evidence towards the ability of SCFAs to reduce and  
43 treat tumors, the studies reporting benefit in humans has been less convincing.

44 There is a lack of evidence on the benefit of increasing SCFA concentrations to protect against  
45 CRC in human populations. The initial case/control studies that investigated SCFA concentrations  
46 in CRC found that patients with carcinomas had lower concentrations of acetate, butyrate, and  
47 propionate versus either patients with adenomas or individuals without colon tumors (19). Although  
48 this would argue that increasing SCFA concentrations could be protective against tumorigenesis,  
49 fiber supplementation in randomized controlled trials have consistently failed to protect against  
50 tumor recurrence (20). These findings would argue against the utility of treatments that aim to  
51 use SCFAs to reduce or protect against tumorigenesis. Given the lack of clear evidence in human

studies of the benefit of SCFAs in CRC, there is a need for more investigation into this area.

Our study fills some of the current gaps in the literature that relate to the study of SCFAs and CRC in human populations. Specifically, it tests previous case/control findings on SCFA concentrations in individuals with and without tumors. We also test previous suggestions that there is a continuous reduction in SCFA concentrations as tumor severity increases by increasing the number of patients with adenomas in our study. Additionally, we build upon these observations and assesses the utility of using SCFAs and Operational Taxonomic Units (OTUs) as a risk stratification tool of colorectal tumors (adenoma or carcinoma). Collectively, this study provides important information on the replicability of previous findings in humans by extensively studying how SCFAs are associated with colorectal tumors.

To accomplish this task we directly measured the concentration of acetate, butyrate, and propionate within fecal samples for two different groups. The first group had a sample obtained at a single cross sectional point in time while the second group had samples obtained before (pre-) and after (post-)treatment for colorectal tumors. Additionally, we (i) assessed the affect adding SCFA concentrations to OTU data had on classification of patients with adenoma or carcinoma using the Random Forest algorithm (21), (ii) used PICRUST (22) and metagenomic sequencing to assess the presence of genes involved in SCFA synthesis, and (iii) analyzed how well 16S rRNA gene sequencing predicts SCFA concentrations. This investigation provides additional information as to whether SCFAs are decreased in patients with colorectal tumors and provides context as to whether targeting taxa to increase SCFA concentrations is a viable option to protect against colon tumorigenesis.

## Results

**Decreased SCFA concentrations are not associated with tumors.** We used high-performance liquid chromatography (HPLC) to measure acetate, butyrate, and propionate concentrations of frozen fecal samples from 490 individuals at a cross-sectional point in time. There was no difference between individuals without colon tumors (n=172) and patients with either an adenoma (n=198) or carcinoma (n=120) for any of the SCFAs measured after multiple comparison correction (P-value > 0.15) [Figure 1A - 1C]. We next measured the concentration of SCFAs in 67 patients with an adenoma (n=41) or carcinoma (n=26) in which we had pre- and post-treatment fecal samples. Although there was a general trend for increasing acetate, butyrate, and propionate concentrations after treatment for tumors, there was no significant difference pre- and post-treatment for patients with adenoma (P-value > 0.20) or carcinoma (P-value > 0.80) [Figure 1D - 1F]. Even though there was no difference in SCFA concentrations between individuals with normal colons and those with tumors, this information could still be important to help classify disease.

**Random Forest models with SCFA concentrations do not classify tumors better.** SCFA concentrations could improve prediction of tumors based on specific bacterial community structures. Our OTU data can be used in combination with SCFAs to assess whether there is a community dependent context to SCFA classification of tumors. Using the Random Forest algorithm we built models with OTU abundance data only or OTU abundances and SCFA concentrations to classify normal versus adenoma and normal versus carcinoma fecal samples. For adenoma and carcinoma models, there was no difference between the median AUC of models with or without SCFA concentrations (P-value > 0.05) [Figure 2]. Although including SCFA concentrations did not improve classification of colorectal tumors using Random Forest models, it is possible that the genes for enzymes involved in SCFA synthesis may vary based on the type of colorectal tumor; where a smaller number of taxa are responsible for the observed SCFA concentrations in patients with colorectal tumors.

**Changes in genes for enzymes involved in SCFA synthesis are not associated with tumors.** Using a list of specific genes that are important for the synthesis of SCFAs [Table S1], we looked for differences in gene abundance between individuals without colon tumors and patients with

adenomas or carcinomas. First, using imputed gene relative abundance based on 16S rRNA gene sequencing we found no difference in any of the genes involved with acetate, butyrate, or propionate synthesis (P-value > 0.90) [Table S2]. This similarity between groups is highlighted by visualizing genes important in butyrate synthesis [Figure 3A]. Using a paired Wilcoxon rank-sum test, there also was no difference in imputed gene relative abundance between pre- and post-treatment samples for any genes involved with SCFA synthesis (P-value > 0.70) [Table S3]. Next, we took a subset of these 490 fecal samples (n=85) and used metagenomic sequencing to confirm these results. Like the imputed gene results, metagenomic analysis found that there was no difference in any of the genes involved in SCFA synthesis between individuals without colon tumors (n=29) and patients with adenoma (n=28) or carcinoma (n=28) (P-value > 0.70) [Table S4]. This lack of difference is highlighted when we visualize the results for butyrate kinase [Figure 3B]. These observations provide evidence that gene prevalence does not change due to colorectal tumors.

**Expected taxa are associated with higher SCFA concentrations regardless of tumor status.**

Using OTU data we built Random Forest models to classify higher than median and lower than median SCFA concentrations. Overall, OTU data had a reasonable ability to classify high and low SCFA concentrations [Figure S1A]. However, these models tended to be over fit, suggesting that rarer taxa may be important for this classification [Figure S1A]. The most important OTUs to these models (assessed with mean decrease in accuracy (MDA)) were taxa that are normally associated with SCFA production [Figure S1B]. These results highlight that within our data, SCFA concentrations are associated with taxa known to produce acetate, butyrate, and propionate. Additionally, OTUs associated with these taxa are the most important to models that can classify high and low SCFA concentrations. Overall, our results are robust and do not support the hypothesis that differences in SCFA concentrations are associated with colorectal tumors.

## Discussion

The observations from this study do not support the hypothesis that SCFA concentrations are lower in individuals with tumors. Whether we directly measured the SCFA concentration or investigated genes associated with their production, no difference could be identified [Figure 1 & 3]. Further, no benefit could be found in using the concentrations to help classify individuals with and without tumors [Figure 2]. These observations are in stark contrast to some of the previous literature.

Much of the previous research on SCFA benefit to human CRC has been illustrated in model systems (16). Many SCFAs are produced through the breakdown of fiber (14) and a recent study in mice found that fiber supplementation increased SCFA concentrations and decreased tumor burden (18). Additionally, SCFAs such as butyrate can inhibit tumor growth in *in vitro* experiments (17). Yet, observations in humans has been mixed. Previous case/control studies found associations with lower SCFA concentrations in individuals with carcinoma tumors (19). However, individual randomized controlled trials and a recent meta-analysis on fiber supplementation to prevent tumor recurrence has found no benefit (20, 23). Our results align with what has been reported in randomized-controlled trials, that SCFAs do not provide general protection against colorectal tumors. It is possible though that there are specific instances where SCFAs may be beneficial.

One limitation of ours and others research into the effect of SCFAs in CRC has been that all tumors are treated as the same type. However, there are known differences in the types of mutations that occur (24) and treating all tumors as equal may actually hide any benefit that could be found in specific subsets of individuals. Similar to the idea of specific immunotherapy for specific tumors (25), SCFAs may have beneficial effects for specific types of colorectal tumors. Future research will need to test if this is a valid hypothesis. Although there are limitations with the current research on SCFAs and colorectal tumors, evidence is building that these specific metabolites may not be protective. Yet, taxa that are associated with SCFA production are consistently higher in normal colons than those with carcinomas (10, 11, 26).

The potential protection against colorectal cancers may not be from SCFAs even though taxa associated with their production are higher in individuals with normal colons versus patients with

151 carcinomas (10, 11, 26). Protection could be via a different pathway and by extension other  
152 metabolites that have not been extensively studied. Alternatively, protection may not occur via a  
153 metabolite but instead through niche exclusion of mouth-associated microbes (e.g. *Fusobacterium*,  
154 *Porphyromonas*, *Parvimonas*, *Peptostreptococcus* (12, 13)). The idea of niche exclusion is similar  
155 to how the community protects against *Clostridium difficile* infection (27) with chronic inflammation  
156 replacing the role of antibiotics. Although we did not find lower concentrations of SCFAs associated  
157 with colorectal tumors, we think that there are many exciting new avenues to explore because of  
158 these results



## Conclusions

Our observations found no difference in SCFA concentration, their utility as a classification tool, and for genes for enzymes involved in SCFA synthesis between individuals with normal colons and patients with either adenoma or carcinoma tumors. Although these results are different than other reports in the literature, they do align with the randomized controlled trials that have tested fiber use in preventing colorectal tumor recurrence. Overall, these results suggest that the SCFAs produced by resident microbes do not protect against tumor. By focusing on other types of metabolites, the identification of more promising therapeutic options for use in treating colorectal cancer may be found.

## Materials and Methods

**Study design and sampling.** The overall protocol has been described in detail previously (28, 29). In brief, this study used fecal samples obtained at either a single cross-sectional time point (n=490) or from before (pre-) and after (post-) treatment of a patient's tumor (n=67). For patients undergoing treatment for their tumor the length of time between their initial and follow up sample ranged from 188 - 546 days. Our use of treatment has been previously defined as encompassing removal of a tumor with or without chemotherapy and radiation (28). Diagnosis of tumor was made by colonoscopic examination and histopathological review of biopsies obtained (28, 29). The University of Michigan Institutional Review Board approved the study and informed consent was obtained from all participants in accordance to the guidelines set out by the Helsinki Declaration.

**Measuring specific SCFAs.** Our protocol for the measurement of acetate, butyrate, and propionate followed a previously published protocol that used a High-Performance Liquid Chromatography (HPLC) machine (30). The following changes to this protocol included the use of frozen fecal samples suspended in 1ml of PBS instead of fecal suspensions in DNA Genotek OmniGut tubes, and the use of the actual weight of fecal samples instead of the average weight for SCFA concentration normalizations. These methodological changes did not affect the overall median concentrations of these SCFAs between the two studies (see Table 1 (30) and Figure 1 here).

**16s rRNA gene sequencing.** The workflow and processing have been previously described (28, 31, 32). The major differences from these previous reports include: the use of version 1.39.5 of the mothur software package and clustering Operational Taxonomic Units (OTUs) at 97% similarity using the OptClust algorithm (33).

**Generating imputed metagenomes.** The use of PICRUSt version 1.1.2 with the recommended standard operating protocol (22) was used. Briefly, the mothur shared file and metadata was converted into a biom formatted table using the biom convert function, the subsequent biom file was processed with the 'normalize\_by\_copy\_number.py' function, and subsequent imputed metagenomes created using the 'predict\_metagenomes.py' function.

**Obtaining Operational Protein Families from metagenomes.** A subset of the cross-sectional

group (n=490) containing a total of 85 individuals (normal n=29, adenoma n=28, and carcinoma n=28) was shotgun sequenced on an Illumina HiSeq using 125 bp paired end reads and a previously described method (34). Briefly, the sequences were quality filtered and sequences aligning to the human genome were removed prior to contig assembly with MEGAHIT (35). Open Reading Frames (ORFs) were identified using Prodigal (36), counts generated using Diamond (37), subsequent clustering into Operational Protein Families (OPFs) used mmseq2 (38), and OPF alignment used the KEGG database (39).

**Pulling genes involved with SCFA synthesis.** Specific genes located near the end of the pathways involved in the synthesis of acetate, butyrate, and propionate were analyzed for any differences between individuals with normal colons and those with tumors. These genes were based on pathways from KEGG as well as previous research (39, 40) and a list can be found in the supplemental material [Table S1].

**Random Forest models.** The model was first trained on 80% of the data and then tested on the held out 20% (80/20 split) using the Random Forest algorithm for classification models (21). This was repeated on 100 different 80/20 splits of the data to generate a reasonable range for the AUC of the model. The reported AUCs, unless otherwise specified, are for the test sets. The classification models were built to group normal versus adenoma, normal versus carcinoma, and high versus low SCFA concentrations.

**Statistical analysis workflow.** All analysis was performed using the statistical language R (41). Generally, a Kruskal-Wallis rank sum test with a Dunn's post-hoc test was used to assess differences between the groups used. Where appropriate Benjamini-Hochberg was used to correct for multiple comparisons (42). First, we assessed differences in SCFA concentrations measured by HPLC between individuals with normal colons and patients with tumors (adenoma or carcinoma). We then analyzed whether SCFA concentrations changed in patients with an adenoma or carcinoma pre- versus post-treatment. Next, we assessed whether OTUs alone or OTUs and SCFAs were better able to classify individuals with and without tumor using Random Forest models. Next, the imputed gene counts of important mediators of SCFA synthesis was tested. Additionally, the counts generated for OPFs that matched important genes involved with SCFA creation were analyzed.

223 Finally, models to classify high or low SCFA concentration based on the median of each SCFA and  
224 16S rRNA gene sequencing data was created using the Random Forest algorithm.

## Acknowledgements

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Kwi Kim and Thomas M Schmidt for their help in running the short-chain fatty acid analysis on the High-Performance Liquid Chromatography machine at the University of Michigan. Salary support for Marc A. Sze came from the Canadian Institute of Health Research and NIH grant UL1TR002240. Salary support for Patrick D. Schloss came from NIH grants P30DK034933 and 1R01CA215574.

## References

1. **Hagggar F, Boushey R.** 2009. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery* **22**:191–197. doi:10.1055/s-0029-1242458.
2. **Siegel RL, Miller KD, Jemal A.** 2016. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66**:7–30. doi:10.3322/caac.21332.
3. **Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K.** 2000. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from sweden, denmark, and finland. *New England Journal of Medicine* **343**:78–85. doi:10.1056/nejm200007133430201.
4. **Fliss-Isakov N, Zelber-Sagi S, Webb M, Halpern Z, Kariv R.** 2017. Smoking habits are strongly associated with colorectal polyps in a population-based case-control study. *Journal of Clinical Gastroenterology* 1. doi:10.1097/mcg.0000000000000935.
5. **Lee J, Jeon JY, Meyerhardt JA.** 2015. Diet and lifestyle in survivors of colorectal cancer. *Hematology/Oncology Clinics of North America* **29**:1–27. doi:10.1016/j.hoc.2014.09.005.
6. **Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M.** 2011. Genomic analysis identifies association of fusobacterium with colorectal carcinoma. *Genome Research* **22**:292–298. doi:10.1101/gr.126573.111.
7. **Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD.** 2013. The gut microbiome modulates colon tumorigenesis. *mBio* **4**:e00692–13–e00692–13. doi:10.1128/mbio.00692-13.
8. **Baxter NT, Zackular JP, Chen GY, Schloss PD.** 2014. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. *Microbiome* **2**:20. doi:10.1186/2049-2618-2-20.
9. **Zackular JP, Baxter NT, Chen GY, Schloss PD.** 2015. Manipulation of the gut microbiota

reveals role in colon tumorigenesis. *mSphere* **1**:e00001–15. doi:10.1128/msphere.00001-15.

10. **Shah MS, DeSantis TZ, Weinmaier T, McMurdie PJ, Cope JL, Altrichter A, Yamal J-M, Hollister EB.** 2017. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. *Gut* **67**:882–891. doi:10.1136/gutjnl-2016-313189.

11. **Sze MA, Schloss PD.** 2018. Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors. doi:10.1101/285486.

12. **Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Bohm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Nhieu JTV, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, Knebel Doeberitz M von, Sobhani I, Bork P.** 2014. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology* **10**:766–766. doi:10.15252/msb.20145645.

13. **Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* **8**. doi:10.1186/s13073-016-0290-3.

14. **Holscher HD.** 2017. Dietary fiber and prebiotics and the gastrointestinal microbiota. *Gut Microbes* **8**:172–184. doi:10.1080/19490976.2017.1290756.

15. **Louis P, Flint HJ.** 2016. Formation of propionate and butyrate by the human colonic microbiota. *Environmental Microbiology* **19**:29–41. doi:10.1111/1462-2920.13589.

16. **O’Keefe SJD.** 2016. Diet, microorganisms and their metabolites and colon cancer. *Nature Reviews Gastroenterology & Hepatology* **13**:691–706. doi:10.1038/nrgastro.2016.165.

17. **Encarnação JC, Pires AS, Amaral RA, Gonçalves TJ, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmiento-Ribeiro AB, Abrantes AM, Botelho MF.** 2018. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. *The Journal of Nutritional Biochemistry* **56**:183–192. doi:10.1016/j.jnutbio.2018.02.018.

18. **Bishehsari F, Engen P, Preite N, Tuncil Y, Naqib A, Shaikh M, Rossi M, Wilber S, Green**

- 282 **S, Hamaker B, Khazaie K, Voigt R, Forsyth C, Keshavarzian A.** 2018. Dietary fiber treatment  
283 corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon  
284 carcinogenesis. *Genes* **9**:102. doi:10.3390/genes9020102.
- 285 19. **Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, Nomoto**  
286 **K, Onodera H.** 2013. Changes of the intestinal microbiota, short chain fatty acids, and  
287 fecal pH in patients with colorectal cancer. *Digestive Diseases and Sciences* **58**:1717–1726.  
288 doi:10.1007/s10620-012-2526-4.
- 289 20. **Yao Y, Suo T, Andersson R, Cao Y, Wang C, Lu J, Chui E.** 2017. Dietary fibre for the  
290 prevention of recurrent colorectal adenomas and carcinomas. *Cochrane Database of Systematic*  
291 *Reviews*. doi:10.1002/14651858.cd003430.pub2.
- 292 21. **Liaw A, Wiener M.** 2002. Classification and regression by randomForest. *R News* **2**:18–22.
- 293 22. **Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC,**  
294 **Burkepile DE, Thurber RLV, Knight R, Beiko RG, Huttenhower C.** 2013. Predictive functional  
295 profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology*  
296 **31**:814–821. doi:10.1038/nbt.2676.
- 297 23. **Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R,**  
298 **Cooper MR, Kikendall JW, Cahill J, Freedman L, Marshall J, Schoen RE, Slattery M.** 2000.  
299 Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. *New England*  
300 *Journal of Medicine* **342**:1149–1155. doi:10.1056/nejm200004203421601.
- 301 24. **Fearon ER, Vogelstein B.** 1990. A genetic model for colorectal tumorigenesis. *Cell*  
302 **61**:759–767. doi:10.1016/0092-8674(90)90186-i.
- 303 25. **Thomas X, Heiblig M.** 2016. The development of agents targeting the BCR-ABL tyrosine  
304 kinase as philadelphia chromosome-positive acute lymphoblastic leukemia treatment. *Expert*  
305 *Opinion on Drug Discovery* **11**:1061–1070. doi:10.1080/17460441.2016.1227318.
- 306 26. **Sze MA, Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2017. Normalization of the



307 microbiota in patients after treatment for colonic lesions. *Microbiome* **5**. doi:10.1186/s40168-017-0366-3.

308 27. **Theriot CM, Young VB**. 2015. Interactions between the gastrointestinal microbiome and  
 309 *Clostridium difficile*. *Annual Review of Microbiology* **69**:445–461. doi:10.1146/annurev-micro-091014-104115.

310 28. **Sze MA, Baxter NT, Ruffin MT, Rogers MAM, Schloss PD**. 2017. Normalization of the  
 311 microbiota in patients after treatment for colonic lesions. *Microbiome* **5**. doi:10.1186/s40168-017-0366-3.

312 29. **Baxter NT, Ruffin MT, Rogers MAM, Schloss PD**. 2016. Microbiota-based model improves  
 313 the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* **8**.  
 314 doi:10.1186/s13073-016-0290-3.

315 30. **Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, Schmidt TM**. 2016.  
 316 Variable responses of human microbiomes to dietary supplementation with resistant starch.  
 317 *Microbiome* **4**. doi:10.1186/s40168-016-0178-x.

318 31. **Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA,**  
 319 **Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber CF**.  
 320 2009. Introducing mothur: Open-source, platform-independent, community-supported software  
 321 for describing and comparing microbial communities. *Applied and Environmental Microbiology*  
 322 **75**:7537–7541. doi:10.1128/aem.01541-09.

323 32. **Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD**. 2013. Development of a  
 324 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on  
 325 the MiSeq illumina sequencing platform. *Applied and Environmental Microbiology* **79**:5112–5120.  
 326 doi:10.1128/aem.01043-13.

327 33. **Westcott SL, Schloss PD**. 2017. OptiClust, an improved method for assigning  
 328 amplicon-based sequence data to operational taxonomic units. *mSphere* **2**:e00073–17.  
 329 doi:10.1128/mspheredirect.00073-17.

330 34. **Hannigan GD, Duhaime MB, Ruffin MT, Koumpouras CC, Schloss PD**. 2017. Diagnostic

331 potential & the interactive dynamics of the colorectal cancer virome. doi:10.1101/152868.

332 35. **Li D, Liu C-M, Luo R, Sadakane K, Lam T-W.** 2015. MEGAHIT: An ultra-fast single-node  
333 solution for large and complex metagenomics assembly via succinct de bruijn graph. *Bioinformatics*  
334 **31**:1674–1676. doi:10.1093/bioinformatics/btv033.

335 36. **Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ.** 2010. Prodigal:  
336 Prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* **11**:119.  
337 doi:10.1186/1471-2105-11-119.

338 37. **Buchfink B, Xie C, Huson DH.** 2014. Fast and sensitive protein alignment using DIAMOND.  
339 *Nature Methods* **12**:59–60. doi:10.1038/nmeth.3176.

340 38. **Steinegger M, Söding J.** 2017. MMseqs2 enables sensitive protein sequence searching for  
341 the analysis of massive data sets. *Nature Biotechnology*. doi:10.1038/nbt.3988.

342 39. **Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M.** 2015. KEGG as a  
343 reference resource for gene and protein annotation. *Nucleic Acids Research* **44**:D457–D462.  
344 doi:10.1093/nar/gkv1070.

345 40. **Baxter NT, Zackular JP, Chen GY, Schloss PD.** 2014. Structure of the gut microbiome  
346 following colonization with human feces determines colonic tumor burden. *Microbiome* **2**:20.  
347 doi:10.1186/2049-2618-2-20.

348 41. **R Core Team.** 2017. R: A language and environment for statistical computing. R Foundation  
349 for Statistical Computing, Vienna, Austria.

350 42. **Benjamini Y, Hochberg Y.** 1995. Controlling the false discovery rate: A practical and powerful  
351 approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*  
352 **57**:289–300.

**Figure 1. No change in SCFA measurements was observed between normal, adenoma, and carcinoma individuals using HPLC.** Acetate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (A). Butyrate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (B). Propionate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (C). The black lines indicate the median SCFA concentration. Acetate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (D). Butyrate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (E). Propionate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (F). The black dots and lines represent the median change in SCFA concentration.

**Figure 2. SCFAs do not improve OTU-based Random Forest models.** The area under the curve of 100 different 80/20 split OTU-based normal versus adenoma 10-fold CV models with and without SCFAs (A). The area under the curve of 100 different 80/20 OTU-based normal versus carcinoma 10-fold CV models with and without SCFAs (B). The black line represents the median AUC. The dotted line highlights an AUC of 0.5.

**Figure 3. No change in butyrate producing genes identified between normal, adenoma, and carcinoma individuals.** Imputed gene relative abundance of important butyrate pathway genes using PICRUSt (A). Counts per million (corrected for size and number of contigs in an OPF) for the Butyrate Kinase gene (B). The other butyrate pathway genes from the PICRUSt analysis did not align to any of the OPFs in the metagenome analysis.

**Figure S1. OTU-based Random Forest models of SCFA concentrations.** The train and test results of 100 different 80/20 OTU-based models with 10-fold CV based on higher or lower than the median SCFA concentration using classification Random Forest (A). The top 10 OTUs based on mean decrease in accuracy (MDA) for each model, colored by their lowest taxonomic identification (B).